BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HemoShear, LLC Awarded $4.3 Million National Institutes of Health (NIH) Grant to Develop Predictive Drug Database


8/25/2011 10:37:20 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that it has been awarded up to $4.3 million in a Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant will fund work profiling the effects of 50 known drugs upon the human blood vessel system (the vasculature) using HemoShear’s proprietary human vascular surrogate system. The database will be valuable in predicting the safety and efficacy of potential new drug candidates. HemoShear will use proprietary bioinformatics methods to develop a predictive vascular gene signature that can be used to score new drug compounds for vascular safety risk. There are no technologies currently available to the pharmaceutical industry to address this need.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES